文献速递白血病

MLL重排急性髓系白血病中复发性CCND3突变

Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2018-01-01

该研究对日本儿童白血病/淋巴瘤研究组AML-05研究中MLL重排急性髓系白血病(AML)患儿样本进行全外显子测序(n=9)和靶向测序(n=56),并分析105例儿童t(8;21) AML和30例成人MLL重排AML样本,另重新分析31例已发表RNA测序数据。发现儿童MLL重排AML中CCND3突变占8.9%,成人占3.3%,而t(8;21) AML无CCND3突变;CDK4/6抑制剂可阻断细胞周期并抑制增殖。

要点

  • 儿童MLL重排AML中CCND3突变检出率为8.9%(5例),成人为3.3%(2例)。
  • 儿童t(8;21) AML中CCND1突变2.9%(3例)、CCND2突变7.6%(8例),未发现CCND3突变。
  • 伴共存突变的儿童MLL-MLLT3重排AML患者无复发生存和总生存显著低于无共存突变者(P=.048和.046)。

核心结论

  • MLL重排AML中D型周期蛋白基因呈现亚型特异性突变模式,CCND3突变为复发性事件,CDK4/6抑制剂可阻断G1至S期进程并损害增殖,提示潜在治疗策略。

研究设计与样本

  • 对日本儿童白血病/淋巴瘤研究组AML-05研究中儿童MLL重排AML患者样本行全外显子测序(n=9)和靶向测序(n=56)。
  • 另分析105例儿童t(8;21) AML样本和30例成人MLL重排AML样本,并重新分析既往发表的31例患者RNA测序数据。

主要发现

  • 儿童MLL重排AML患者共检出115个突变(2.1个突变/患者),信号通路基因突变最常见(60.7%)。
  • 表观遗传调控基因突变占21.4%,转录因子基因突变占16.1%,黏连蛋白复合物基因突变占8.9%。
  • 儿童MLL重排AML中CCND3突变5例(8.9%),成人MLL重排AML中CCND3突变2例(3.3%)。
  • 儿童t(8;21) AML中CCND1突变3例(2.9%)、CCND2突变8例(7.6%),未发现CCND3突变。
  • 伴共存突变的儿童MLL-MLLT3重排AML患者(n=16)无复发生存和总生存显著低于无共存突变者(n=9)(P=.048和.046)。

关键数值与推荐

  • 儿童MLL重排AML中信号通路基因突变频率60.7%,表观遗传调控基因21.4%,转录因子基因16.1%,黏连蛋白复合物基因8.9%。
  • 儿童MLL重排AML中CCND3突变频率8.9%(5例),成人MLL重排AML中3.3%(2例)。
  • 儿童t(8;21) AML中CCND1突变频率2.9%(3例),CCND2突变频率7.6%(8例),CCND3突变0例。
  • 伴共存突变(n=16)与无共存突变(n=9)的儿童MLL-MLLT3重排AML患者比较,无复发生存P=.048,总生存P=.046。

临床怎么用

  • MLL重排AML细胞系经CDK4/6抑制剂abemaciclib和palbociclib处理后,G1至S期细胞周期进程被阻断且增殖受损。
  • 作者认为这些数据提供了MLL重排AML遗传学见解并提示治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In acute myeloid leukemia (AML), MLL (KMT2A) rearrangements are among the most frequent chromosomal abnormalities; however, knowledge of the genetic landscape of MLL-rearranged AML is limited. In this study, we performed whole-exome sequencing (n = 9) and targeted sequencing (n = 56) of samples from pediatric MLL-rearranged AML patients enrolled in the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study. Additionally, we analyzed 105 pediatric t(8;21) AML samples and 30 adult MLL-rearranged AML samples. RNA-sequencing data from 31 patients published in a previous study were also reanalyzed. As a result, we identified 115 mutations in pediatric MLL-rearranged AML patients (2.1 mutations/patient), with mutations in signaling pathway genes being the most frequently detected (60.7%). Mutations in genes associated with epigenetic regulation (21.4%), transcription factors (16.1%), and the cohesin complex (8.9%) were also commonly detected. Novel CCND3 mutations were identified in 5 pediatric MLL-rearranged AML patients (8.9%) and 2 adult MLL-rearranged AML patients (3.3%). Recurrent mutations of CCND1 (n = 3, 2.9%) and CCND2 (n = 8, 7.6%) were found in pediatric t(8;21) AML patients, whereas no CCND3 mutations were found, suggesting that D-type cyclins exhibit a subtype-specific mutation pattern in AML. Treatment of MLL-rearranged AML cell lines with CDK4/6 inhibitors (abemaciclib and palbociclib) blocked G1 to S phase cell-cycle progression and impaired proliferation. Pediatric MLL-MLLT3-rearranged AML patients with coexisting mutations (n = 16) had significantly reduced relapse-free survival and overall survival compared with those without coexisting mutations (n = 9) (P = .048 and .046, respectively). These data provide insights into the genetics of MLL-rearranged AML and suggest therapeutic strategies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Matsuo H, Yoshida K, Fukumura K, et al. Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia. Blood Adv. 2018. PMID: 30381403. doi:10.1182/bloodadvances.2018019398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。